Navigation Links
Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
Date:3/25/2008

tors including hypertension, obesity, diastolic dysfunction, inflammation, diabetes and sleep apnea.

About Astellas

Astellas Pharma US, Inc., located in Deerfield, Illinois, is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organization is committed to becoming a global category leader in focused areas by combining outstanding R&D and marketing capabilities. In the US, Astellas markets products in the areas of Immunology, Urology, Anti-Infectives, Cardiovascular and Dermatology. For more information about Astellas Pharma US, Inc., please visit our website at http://www.astellas.com/us.

About Cardiome

Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with two late-stage clinical drug programs focused on atrial arrhythmia (intravenous and oral dosing), a Phase 1 program for GED-aPC, an engineered analog of recombinant human activated Protein C, and a pre-clinical program directed at improving cardiovascular function.

Vernakalant (iv) is the intravenous formulation of an investigational drug being evaluated for the acute conversion of atrial fibrillation. Positive top-line results from two pivotal Phase 3 trials for vernakalant (iv), called ACT 1 and ACT 3, were released in December 2004 and September 2005. Cardiome's co-development partner Astellas Pharma US, Inc. submitted a New Drug Application for vernakalant (iv) in December 2006. Positive top-line results from an additional Phase 3 study evaluating patients with post-operative atrial arrhythmia, called ACT 2, were released in June 2007. An open-label safety study evaluating recent-onset AF patients, called ACT 4, has completed.

Vernakalant (oral) is being investigated as a chronic-use oral drug for the main
'/>"/>

SOURCE Astellas Pharma US, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
3. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
4. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
5. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
6. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
9. Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
10. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
11. IDM Pharma Announces Updated Phase 2 UVIDEM(R) Results Showing Durable Disease Control and Tolerability in Advanced Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... INDIANAPOLIS , Aug. 27, 2015  Eli Lilly ... Morgan Stanley Global Healthcare Conference on Thursday, September 17, ... and president of Lilly Oncology and Richard Gaynor ... medical affairs for Lilly Oncology, will participate in a ... A live audio webcast will be available ...
(Date:8/27/2015)... Ohio , Aug. 27, 2015  A mere ... to Booz Allen Hamilton . A new ... product development inefficiencies are impeding and disrupting manufacturers, success. ... Cut Waste and Improve Value In Product Development Processes ... of inaccessible data and how it affects the product ...
(Date:8/27/2015)... and TORONTO , Aug. ... (OTCQB: GNBT) today announced the issuance of a white ... proprietary buccal insulin spray product.  The white paper was ... the Company,s stockholders by Dr. James H. Anderson, ... white paper may be viewed online on the Generex ...
Breaking Medicine Technology:Lilly to Participate in Morgan Stanley Global Healthcare Conference 2New White Paper Reveals How Manufacturers Can Improve Product Development Processes 2Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4
... June 20, 2011 Inogen has been honored with ... Inogen One Portable Oxygen Concentrator.  The Medical Design Excellence ... recognizes contributions and advances in the design of medical ... Goleta, California based Inogen, Inc. is used to provide ...
... approximately 50 million unnecessary visits to primary care physicians ... with increased self-care, including the safe and effective use ... analysis of health management options. These findings—along with a ... of the launch of Your Health at Hand, ...
Cached Medicine Technology:Inogen One Wins Gold Medical Design Excellence Award 2Research Finds Greater Focus on Self-Care Would Save Patients and U.S. Healthcare System Over $5 Billion Annually 2Research Finds Greater Focus on Self-Care Would Save Patients and U.S. Healthcare System Over $5 Billion Annually 3Research Finds Greater Focus on Self-Care Would Save Patients and U.S. Healthcare System Over $5 Billion Annually 4
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Susan ... edge procedure to relieve vaginal discomfort due to pre- and post-menopause, chemotherapy, and child ... a CO2 laser, which delivers controlled energy to the vaginal tissue, revitalizing cells so ...
(Date:8/27/2015)... ... August 27, 2015 , ... Since its launch ... to having twelve offices in three counties, LA, Orange and San Bernardino. ... region. Founded by Dr. Richy Agajanian, the Oncology Institute of Hope and ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... California including Los Angeles, Riverside, San Bernardino, and Orange County. , ... executive physical exams are offered annually at all of its locations. Executive ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... today that they have launched their new corporate website http://www.Z-Medica.com , to ... a product-focused website that was launched last year. , “We launched a ...
(Date:8/27/2015)... Newport Beach, CA (PRWEB) , ... August 27, ... ... services and products, announced today that the new issue of Chairside® magazine, its ... the latest issue, Volume 10, Issue 3, as well as past issues of ...
Breaking Medicine News(10 mins):Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 2Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 3Health News:California’s Largest Private Oncology Practice Serves 50,000 Patients in 8 years 2Health News:Healthpointe Now Offering Executive Physicals 2Health News:Z-Medica® Launches New Corporate Website 2Health News:Glidewell Laboratories Releases Latest Issue of Restorative Dentistry Magazine Chairside in Print and Online 2Health News:Glidewell Laboratories Releases Latest Issue of Restorative Dentistry Magazine Chairside in Print and Online 3
... Administration (FDA) approved a gel that promises less ... FDA had initially rejected Lifecore Biomedical Inc.'s Intergel, ... gynecologic operations. // ,The gel, formally ... to reduce adhesions, internal scar tissue that can ...
... protein released by damaged heart tissue may be a helpful ... Performing heart bypass surgery or angioplasty on patients with elevated ... estimated 40 percent. ,// ,"Any sign of heart ... amount, was a sign that the patient was at high ...
... it shows that warfarin and aspirin are equally effective in ... prevents blood clotting by stopping platelets from clumping together, while ... both are known to help prevent blood clots in the ... thought that warfarin is more effective at preventing stroke, but ...
... has a similar impact on the body to the ... chronic disorders such as heart disease and diabetes, researchers ... people spend asleep per night in more developed countries ... change has been made to accommodate increased demands of ...
... time, the US Food and Drug Administration (FDA) has approved ... by New Jersey-based Johnson & Johnson, is a one-and-three-quarter-inch patch ... an alternative to birth control pills. // ,The ... period. Ortho Evra can be worn on the lower abdomen, ...
... found a way of creating brain cells out of bone ... Parkinson's disease. At the Peterson Medical College scientists grew stem ... growth factors and other chemicals and found they could get ... cells form muscle, bone, cartilage and fat. The researchers say ...
Cached Medicine News:Health News:Deprived sleep leads to ageing 2
The reliable and easy-to-use 3900/P pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
The reliable and easy-to-use 3800 pulse oximeter is now more advanced - featuring TruTrak+ technology, the proprietary clinical motion algorithm from Datex+-Ohmeda....
... can operate in two additional modes. The ... creating a fully featured handheld pulse oximeter, ... used to upgrade existing equipment through the ... or software upgrades to improve the performance ...
... The stylish Avant® 9600s simple functionality, ... of memory makes it well-suited for ... proven digital pulse oximetry, the Avant ... rugged durability. The 9600 provides a ...
Medicine Products: